MX2022005158A - Tratamiento de nefropatia diabetica con un estimulador de guanilato ciclasa soluble (sgc). - Google Patents

Tratamiento de nefropatia diabetica con un estimulador de guanilato ciclasa soluble (sgc).

Info

Publication number
MX2022005158A
MX2022005158A MX2022005158A MX2022005158A MX2022005158A MX 2022005158 A MX2022005158 A MX 2022005158A MX 2022005158 A MX2022005158 A MX 2022005158A MX 2022005158 A MX2022005158 A MX 2022005158A MX 2022005158 A MX2022005158 A MX 2022005158A
Authority
MX
Mexico
Prior art keywords
diabetic nephropathy
treatment
sgc stimulator
sgc
stimulator
Prior art date
Application number
MX2022005158A
Other languages
English (en)
Inventor
Albert Thomas Profy
John P Hanrahan
Original Assignee
Cyclerion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclerion Therapeutics Inc filed Critical Cyclerion Therapeutics Inc
Publication of MX2022005158A publication Critical patent/MX2022005158A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un método para tratar sujetos con nefropatía diabética mediante la administración de ciertas dosis del Compuesto I, un estimulador de la guanilato ciclasa soluble (sGC), solo o en terapia de combinación. (ver Fórmula) Compuesto I.
MX2022005158A 2019-10-29 2020-10-28 Tratamiento de nefropatia diabetica con un estimulador de guanilato ciclasa soluble (sgc). MX2022005158A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962927454P 2019-10-29 2019-10-29
US202062993972P 2020-03-24 2020-03-24
PCT/US2020/057741 WO2021086967A1 (en) 2019-10-29 2020-10-28 Treatment of diabetic nephropathy with an sgc stimulator

Publications (1)

Publication Number Publication Date
MX2022005158A true MX2022005158A (es) 2022-06-08

Family

ID=73856564

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005158A MX2022005158A (es) 2019-10-29 2020-10-28 Tratamiento de nefropatia diabetica con un estimulador de guanilato ciclasa soluble (sgc).

Country Status (11)

Country Link
US (1) US20240165114A1 (es)
EP (1) EP4051281A1 (es)
JP (1) JP2023501344A (es)
KR (1) KR20220128984A (es)
CN (1) CN115175683A (es)
AU (1) AU2020372900A1 (es)
BR (1) BR112022008276A2 (es)
CA (1) CA3156536A1 (es)
IL (1) IL292591A (es)
MX (1) MX2022005158A (es)
WO (1) WO2021086967A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116942616A (zh) 2015-11-30 2023-10-27 赛克里翁治疗有限公司 包含sGC刺激剂的固体分散体
WO2019055859A1 (en) * 2017-09-14 2019-03-21 Ironwood Pharmaceuticals, Inc. TREATMENT OF METABOLIC SYNDROME BY SGC STIMULATOR

Also Published As

Publication number Publication date
CA3156536A1 (en) 2021-05-06
CN115175683A (zh) 2022-10-11
BR112022008276A2 (pt) 2022-07-26
JP2023501344A (ja) 2023-01-18
IL292591A (en) 2022-07-01
EP4051281A1 (en) 2022-09-07
KR20220128984A (ko) 2022-09-22
AU2020372900A1 (en) 2022-05-26
US20240165114A1 (en) 2024-05-23
WO2021086967A1 (en) 2021-05-06
AU2020372900A2 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2022015115A (es) Metodos para tratar la insuficiencia cardiaca con activadores de sarcomeros cardiacos.
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
AU2018341331A1 (en) Improvement in cognitive function with fenfluramine
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
TN2019000019A1 (en) Treatment and prevention of sleep disorders
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
PH12021550047A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
EA201691420A1 (ru) Композиции енолазы 1 (eno1) и их применение
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
WO2022081610A8 (en) TREATMENT OF COGNITIVE IMPAIRMENT WITH A CNS-PENETRANT sGC STIMULATOR
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
WO2020079489A3 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2022005158A (es) Tratamiento de nefropatia diabetica con un estimulador de guanilato ciclasa soluble (sgc).
MX2022001647A (es) Terapia de combinacion con vildagliptina y metformina.
MX2021002818A (es) Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k).
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2019004200A (es) Terapia de combinacion.
MX2022008632A (es) Agente de union a ccr5 para el tratamiento de cancer metastasico positivo para ccr5.